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Abstract: Breast cancer is one of the most frequently diagnosed cancers among women in the 
western world. Due to the aggressive behaviour of some specific types and the possibility of an early 
diagnosis, breast cancer has been constantly studied. Tumour size, histological type, cellular and nuclear 
characteristics, mitotic index, vascular invasion, hormonal receptors and axillary lymph node status are 
biomarkers routinely used. However, these parameters are not enough to predict the course of this 
disease. Molecular biology advances have made it possible to find new markers, which have already been 
incorporated to the clinical practice. Their ultimate goal is to reduce mortality by identifying women at 
risk for the development of this disease, help diagnosis, determine prognosis, detect recurrences, monitor 
and guide treatment, and in particular cancers they are suited for general screening. Tumour markers in 
breast cancer were ranked in categories reflecting their clinical utility, according to the American College 
of Pathologists.
This article focuses on traditional and new molecular markers stratifying them into categories and 
emphasizing their relevance in the routine evaluation of patients with breast cancer.
© Versita. Warsaw and Springer-Verlag Berlin Heidelberg. All rights reserved.
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1 Introduction
Breast cancer is one of the most frequently diagnosed cancers among women in the western 
world. Due to the aggressive behaviour of some specific types and the possibility of an 
early diagnosis, breast cancer has been constantly studied in relation to diagnostic and 
treatment methods [1].
Morphological features such as tumour size, histological type, cellular and nuclear 
characteristics, mitotic index, necrosis, vascular invasion, hormonal receptors and axillary
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tumour lymph node status are routinely used. However, these parameters are not enough 
to predict the course of the disease. Molecular biology advances have made it possible 
to discover new markers, which have already been incorporated to the clinical practice 
and provide key information about the tumour biological behaviour and the potential 
response to radiation or chemotherapy guiding to the best therapeutics. In connection 
with this, the use of tumour markers panel gives more accurate information than that 
provided by just one factor. The fact described have made the cancer prognostic more 
exact than twenty years ago [2, 3].
Tumour markers (TMs) are biochemical indicators of cancer. Antigens of cellular 
surface, cytoplasm proteins, enzymes and hormones are included among them. In clinical 
practice, the term is used with reference to molecules that can be detected in plasma, body 
fluids, solid tumours, circulating tumor cells, lymph nodes and bone marrow [4], Some 
tumour markers are specific for one type of cancer, whereas others are found in several 
cancer types. Antigens produced by tumour cells or associated to them, are found among 
the specific TMs, making them antigenically different from normal cells. Any protein 
of tumour cells can be a potential antigen. They are specially used to help diagnosis, 
determine prognosis, detect recurrence, monitor and guide treatment, and in particular 
cancers they are adequate for general screening.
1.1 Serum Markers
When TMs are released into bloodstream and reach enough concentrations, their detec­
tion can be used for the following purposes: 1.- screening a healthy population or a high 
risk population for the presence of cancer; 2.- performing a diagnosis of cancer or of a 
specific type of cancer; 3.- determining the prognosis of disease; 4.- monitoring the ther­
apeutic response in patients under radiation or chemotherapy. In breast cancer, there 
are relatively few TMs that can be measured in blood. At present, CA 15-3 mucin and 
carcinoembryonic antigen (CEA) are found among the most utilized ones [5, 6].
1.2 Tissue markers
To detect tissue markers in cancer tissues, immunohistochemical (IHC) and immunofluo- 
recence (IF) techniques can be performed. Enzime-linked immunosorbent assay (ELISA) 
is used to visualize and quantify those markers against which specific monoclonal antibod­
ies are formed. These techniques are very useful to identify intracellular and membrane 
antigens in tissue sections or in specimens obtained by puncture. Hormonal receptor de­
tection by IHC is a widely used technique to evaluate the susceptibility of breast cancer 
to anti-estrogen therapeutics [7].
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1.3 Tumour markers in breast cancer
Under the auspices of the American College of Pathologists in 1999 a multidisciplinary 
group of clinicians, pathologists and experts on statistics considered the use of tumour 
markers as prognostic and predictive factors in breast cancer and classified them into 
categories reflecting their clinical utility.
Factors were ranked in three categories (Table 1):
Category I: markers proven to be of prognostic value and useful in clinical patient 
management
Category II: markers which have been extensively studied clinically and biologically, 
but whose importance remains to be validated in statistical studies.
Category III: any other markers not sufficiently studied to demonstrate their prog­
nostic value.
This categorization consists of a detailed outline of the findings and recommendations 
of the consensus conference group and offers an invaluable help for medical doctors and 
technicians dedicated to the clinical evaluation of breast cancer (Table 1) [8].
Table 1 Biomarkers in breast cancer.
Category I Category II Category III
Tumor size c-erb B2 DNA Ploidy
State of Lymph Nodes p53 Angiogenesis
Micrometastasis Vascular invasion EGFr
Sentinel node Ki 67 bcl-2
Histological grade DNA synthesis pS2





After lymph node status, tumor size (measured at least 2 dimensions and using the single 
greatest one) is the most important prognostic factor for patients with breast cancer. 
Precise assessment of tumor size is necessary to properly stratify the patient, particularly 
since screening mammography has resulted in a steadily increasing proportion of early 
cancers.
1.4.2 Lymph nodes status
The topographic level of nodal involvement and the number of axillary lymph nodes 
with metastasis are highly important prognostic factors since they are correlated to the 
disease-free survival, overall survival, cancer recurrence and failure of treatments.
Unauthenticated
Download Date | 10/3/19 8:58 PM
G. Laguens et al. / Central European Journal of Medicine 1(4) 2006 330-347 333
1.4.3 Micrometastasis
Micrometastasis is defined as a histologically detected tumour foci measuring less than 
2.0 mm. It can be detected by routine hematoxylin and eosin staining, and its prognostic­
value is widely recognized. Immunohistochemistry with anti-cytokeratin antibodies to 
detect unapparent foci of malignant epithelial cells in lymph nodes is even more sensitive. 
Micrometastasis has been correlated to vascular peritumoral invasion and tumour size [9].
1.4.4 Sentinel lymph node
Sentinel node is the first lymph station receiving tumor lymph drainage and is considered 
to be the place where the early metastases are found. Sentinel lymph node biopsy is 
now widely used to evaluate the status of the axilla and is very useful when the ordinary 
pathological evaluation is combined with anti-cytokeratin antibodies [10, 11].
1.4.5 Histological grading
In 1957 Bloom and Richardson [12] developed a grading system based on strict histological 
criteria. It combines tubule formation grade, nuclear features and mitotic figures count. 
These histological factors were scored with numbers from 1 to 3. The obtained point score 
allows tumour grading according to their degree of differentiation, which is an important 
determinant of prognosis.
In 1989, Helpap proposed a modification of this method, including nucleolar findings 
such as size, number and localization [13].
At present, the Nottingham Prognostic Index (NPI) is utilized, which is based on 
tumour size, histological grading and lymph nodes status [14],
1.4.6 Histological type
Some breast cancer types -medullar, tubular, mucinous or colloid carcinoma- are tumours 
with low grade of malignancy, usually with negative lymph nodes and favourable progno­
sis. Poorly differentiated carcinomas such as signet rings, inflammatory carcinoma and 
carcinosarcomas are considered more aggressive. Lobular infiltrating carcinoma exhibits 
a propensity for multicentricity and bilaterality [15].
1.4.7 Mitotic index
The number of mitotic figures in a delimited area of a tumour is an accurate means of 
estimating tumour cell proliferation. High mitotic index is correlated to a poor prognosis. 
This represents a part of the Nottingham combined histological grade (NPI).
1.4.8 Estrogen (ER) and progesterone (PR) receptors
The presence of steroid hormone receptors (estrogen receptor [ER] and progesterone re­
ceptor [PR]) represents a relatively weak prognostic factor for patients with breast can­
cer, but these receptors are the strongest predictive factors for the response to endocrine 
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therapy [16]. In recent years, immunohistochemistry has replaced the ligand-binding bio­
chemical assay for the assessment of ER and PR status. In fact, this method is easier 
to perform and has been shown to be equal to or better than the biochemical assay in 
predicting the response to adjuvant endocrine therapy [17]. Estrogen and progesterone 
are essential hormones for breast growth since both of them bind to the nuclear receptors 
and regulate the transcription of several genes. Estrogens stimulate proliferation of ductal 
epithelial cells in normal mammary glands and play a key role in the development and 
the progression of breast cancer. Thus life-long exposure to estrogen plays an important 
role in development of breast cancer. Studies that have identified risk factors for breast 
cancer have found that women who had menarche at an early age or menopause at a later 
age have a higher risk of breast cancer. This also supports the theory that the number 
of menstrual cycles a woman, and hence the length of exposure to estrogen during her 
lifetime enhance the risk of breast cancer [18].
Several cell cycle regulatory proteins have been implicated in the ER-signaling path­
way involved in estrogen-mediated growth stimulation and antiestrogen-mediated growth 
arrest. A cyclin-dependent kinase inhibitor such as p21 is a component of this pathway 
and can mediate the estrogen action in ER-negative breast cancer cells [19].
Approximately one third of breast cancer are ER-positive and are characterized by 
slow growth, high degree of differentiation, increase of the relapse-free and overall survival 
and good response to anti-estrogen drugs such as Tamoxifen. The antitumour effects of 
Tamoxifen are thought to be caused by its antiestrogen activity, mediated by competitive 
inhibition of estrogen binding to their receptors. However, most ER-positive tumors can 
eventually become resistant to this drug [20].
About 50% of all ER-positive breast tumors are also PR-positive and these double posi­
tive tumors have a mayor benefit with hormonal therapeutics, whereas ER-positive/PR- 
negative ones are very unlikely to equally respond to Tamoxifen.
Estrogen and progesterone receptors are recommended to be measured in both pri­
mary breast cancer and metastasis. In pre and postmenopausal patients, steroid hormone 
receptor status may be useful to identify patients who can benefit from endocrine forms 
of adjuvant therapy. Tamoxifen has been the mainstay of hormonal therapy in not only 
early but also advanced breast for approximately three decades. The availability of novel 
compounds such as aromatase inhibitors and fulvestrant, with different mechanisms of 
action, is changing the scenario of endocrine treatment of postmenopausal patients [21],
1.5 Category II
1.5.1 Her-2/neu (c-erbB-2)
c-erbB-2 is a proto-oncogene encoding a transmembrane glycoprotein with tyrosine-kinase 
activity. This receptor has homology to other family members (EGFR, erbB-3 and 
erbB-4). Immunochemical staining for detecting c-erbB-2 overexpression is more likely to 
be positive than fluorescence in situ hybridization (FISH) for quantifying c-erbB-2 gene 
amplification [22], It is considered as a key prognostic factor in early stages of breast can­
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cer and several studies have shown that they can be used as predictive markers related 
to chemotherapy and antiestrogen therapy responses. It is related to a poor prognosis, 
lymph node metastasis, p53 overexpression and an increase of cell proliferation. C-erbB-2 
amplification is one of the most common genetic mutations associated to breast cancer, 
making them resistant to chemotherapeutic drugs [23].
High levels of c-erbB-2 expression or c-erbB-2 amplification can be used to identify 
patients for whom Trastuzumab (anti- c-erbB-2 antibody) may be of benefit for the treat­
ment of metastasis, recurrent, and/or treatment-refractory, locally unresectable advanced 
breast cancer [24],
1.5.2 Protein 53 (p53)
The role of p53 is to maintain the integrity of genome. The activation of normal p53 leads 
to cell cycle arrest in G1 and induction of DNA repair. If DNA repair fails, p53 promotes 
apoptosis. In cells with loss or mutation of p53, DNA damage remains unrepaired, muta­
tions become fixed in dividing cells and cells turn into a malignant transformation. p53 
gene is located at chromosome 17 pl3.1. Nearly over 50 % of all human tumours posses 
mutations of this gene. Nearly one third of breast cancers have mutations of p53, and 
this is associated with more aggressive and therapeutically refractory tumors [25]. Recent 
immunohistochemical studies suggest that p53 protein accumulation is associated with 
several other adverse prognostic factors such as high tumour grade, high proliferation 
rate, and ER. and PR negativity [26].
1.5.3 Vascular invasion vascular and angiogenesis
Angiogenesis is a process consisting in the growth of new blood vessels from a preexisting 
vascular net. Neovascularization has a dual effect on tumor growth: perfusion supplies 
nutrients and oxygen and newly formed endothelial cells stimulate the growth of tumour 
cells by secreting growth factors. Angiogenesis is a requisite for not only tumour growth 
but also metastasis. A significant correlation between the extent of angiogenesis - mea­
sured through microvessel density- and the probability of metastases was found.
In breast cancer, vessel density has proven to be a significant prognostic indicator 
not only in patients with positive nodes but also in those with negative lymph nodes. 
Patients with a high grade of vascularization have a poor prognosis at early stages of the 
disease [27].
The most widely counting method was developed by Weidner and consists in the use 
of markers to stain endothelial cells. There are different staining methods: (H-E) and 
inmunohistochemistry with anti factor von-Willebrand, anti CD31 (vascular adhesion 
molecule) and anti CD34 (adhesion molecule) [28].
The clinical utility of these surrogate markers of angiogenesis in predicting clinical 
course has become a prognostic help especially with the latest refinements; the compu­
terized morphometric analysis [29, 30]. Experimental and clinical data showed that breast 
carcinoma is an angiogenesis-dependent tumour and its hormonal receptor status is not 
correlated to angiogenesis [31-33].
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1.5.4 Ki 67 (mib 1 antibody)
Proliferation rate in breast cancer can be measured by immunohistochemistry with the 
antibody mib 1, Ki 67. It is a non-histone nuclear protein found in all phases of cell cycle, 
except in GO. Its prognostic value is independent of age, nodal status and hormonal 
status. Nevertheless, it was found that it is inversely correlated with estrogen receptors 
status and indicates a poor prognosis. There may be a direct relationship between cell 
fraction in S-Phase measured by flow cytometry and the IHC tissue detection with Ki 67 
|34],
1.5.5 DNA Synthesis
DNA content can be quantifiable by flow cytometry analysis or image analysis of tissue 
sections with IHC using antibody PCNA (cell nuclear antigen). PCNA is a non-histone 
nuclear protein of 36 Kda functioning as accessory of DNA polymerase 6 and is related 
to DNA synthesis and cellular proliferation. This protein is detected in the late Gl-phase 
of cell cycle, immediately before the onset of S-phase, where its maximum value is found, 
declining during G2 and M. PCNA has shown to be an independent prognostic indicator 
in predicting disease-free and overall survival in breast carcinoma patients [35].
1.6 Category III
1.6.1 DNA Ploidy
In addition to determine S-fraction, DNA analysis is useful for identifying tumours with 
abnormal DNA profiles (aneuploidy). The degree of DNA abnormality is established by 
an index which is the ratio between G0-G1 peak locations of tumour cells and normal 
cells. Until recently this parameter has not been considered as an independent prognostic­
marker and remains in research phase.
Common criteria for classifyng abnormalities of DNA content seem to be inadequate 
for the dynamics of genome instability characterizing human tumors [36].
1.6.2 Vascular endothelial growth factor (VEGF)
VEGF is an important regulator of angiogenesis and vascular permeability and it is 
considered the most powerful mitogen for endothelial cells. It is secreted by tumour cells 
and by stromal monocytes and macrophages, responding to stimuli such as hypoxia or 
cytokines (IL 1, 3, 6 and 10). The level of circulating VEGF provides a less subjective 
analysis than IHC. In breast cancer VEGF is used as a marker of unfavourable prognosis 
since it is associated to recurrence. Because angiogenesis is essential for growth and 
tumour progression, the use of its inhibitors is becoming of interest as co-adjuvant of 
other therapeutics. It has been observed that patients with metastasis have higher levels 
of serum VEGF and could benefit from anti-VEGF treatment [37].
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1.6.3 Epidermal growth factor receptor (EGFR)
EGFR, also known as erbBl receptor, has a tyrosine-kinase activity and it is involved 
in the division of epithelial cells and fibroblasts induced by EGF. It is overexpressed in 
30 % of breast cancer. EGFR. expression in primary breast cancer has been extensively 
investigated in its prognostic and predictive value [38]. It is associated with a shorter 
disease-free period and a decrease of overall survival, showing an inversed relationship 
with the highly significant expression of ER.. Consequently, the response to the hormonal 
therapeutics seems to be impaired. Several anti-EGFR. agents are being clinically tested 
on patients with breast cancer. A better understanding of the EGFR. pathways will 
facilitate the identification of patients prone to respond to these agents [39].
1.6.4 Cathepsin D
One of the most reliable features of malignant cells is their invasiveness. In order to accom­
plish this, malignant cell sub-clones separate from the rest of the tumour mass, penetrate 
the basement membrane, adhere to the matrix components to which they degrade, and 
then they migrate through the vascular basement membrane and reach circulation. Seve­
ral protease families are implied in the degradation of extracellular matrix: plasminogen 
activator urokinase, cathepsins B, D and L and several metalloproteinases. In breast 
cancer, there is a close relationship between high levels of proteases with an unfavorable 
prognosis of the disease.
Cathepsin D (CathD) is a lysosomal aspartylprotease induced by estrogen and growth 
factors that can be expressed not only in ER-positive breast carcinoma but also in ER­
negative ones [40]. CathD overexpression in breast cancer is associated with recurrence, 
metastasis and a shorter disease-free and overall survival [41],
1.6.5 Bcl-2
Bcl-2 is a member of a gene family whose function is to regulate apoptosis.
It is frequently expressed in breast cancer and is related to low rate of proliferation, 
high degree of differentiation, low expression of stromal cathepsin D, DNA diploidy and 
ER. expression.
Bcl-2 expression is more frequent in breast carcinoma of lobular than of ductal type. 
The reason for this difference is unknown, but it could reflect the different histological 
origin of both types of tumours. It is considered that breast cancer expressing this protein 
has more favorable outcome and good response to Tamoxifen [42],
1.7 Tumour markers not included in categorization
1.7.1 Mucins
Mucins are large glycoproteins with high carbohydrate content (50 to 90 % by weight). 
They are expressed by a diversity of normal and malignant epithelial cells. One of the 
most studied ones is MUC1. Cancer-associated MUC1 is incompletely glycosilated. It 
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exposes internal sugar units and non exposed peptide sequences, being essential for the 
normal molecule [5].
Mucins have diverse functions: they mediate in epithelium morphogenesis, cytosketal 
remodeling and downregulate other adhesion molecules. The increase of MUC1 expression 
by tumour cells might facilitate detachment from original tumoral mass and from cellular 
matrix. During the process of bloodborne metastasis, MUC1 can protect tumour cells 
from destruction by natural killer cells or other immune cells [43].
MUC1, is commonly detected in serum such as CA 15.3 or CA 27.29 and can be 
utilized to monitor endocrine or chemotherapy and predict metastasis in advanced disease. 
CA 15.3 is not breast cancer-specific since a proportion of patients with prostate, ovary 
and pancreas cancer also show high serum levels of this mucin. 50% of the patients with 
breast cancer in stage IV and between 10 and 20% in stage II show high levels [44],
CA27.29 is similar to CA15.3 but is more specific. Both mucins can help clinically for 
the follow-up and handling of patients with advanced breast cancer. They are also used 
in asymptomatic population screening. High levels of mucins are associated with a poor 
prognosis and progression in some types of cancers.
Recently another mucin, MUC5B, is being investigated and may be considered as a 
potential marker of tumour cell dissemination to bone marrow [45].
1.7.2 Breast cancer 1 and 2 (BRCA-1 and BRCA-2)
Nearly 5 to 10% of breast cancers are associated with a hereditary predisposition and 
80 % are related to two suppressor genes mutations: BRCA-1 and BRCA-2. These 
genes encode nuclear phosphoproteins interacting with multiple biological processes such 
as damaged DNA repair, regulation of the transcription, centrosome duplication and 
negative regulation of cell cycle. In spontaneous breast cancer gene, mutations are not 
common. The gene encoding BCRA-1 was isolated in chromosome 17 and BRCA-2 
gen was isolated in chromosome 13 [46]. Not every woman expressing these mutated 
suppressor genes will develop breast cancer. BRCA-1 mutation is associated to a poorly 
differentiated, RE negative and Her- 2/neu positive breast carcinoma. This mutation also 
increases the risk of ovarian cancer. On the other hand, mutation of both genes enhances 
the risk of more aggressive bilateral breast cancer and also predisposes to colon, prostate 
and pancreas cancer [47].
1.7.3 Transforming growth factor a (TGFa)
TGFa is a polypeptide closely related to EGF, which has been shown to have a stimu­
latory effect on the growth of some types of breast cancers. The receptor binds both 
EGF and TGF. It can stimulate angiogenesis and cellular proliferation. In breast cancer, 
TGFa overexpression is associated with the presence of positive lymph nodes, absence of 
ER. and poor response to Tamoxifen [48].
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1.7.4 Protease: uPA
Uroquinase-type plasminogen activator (uPA) is a 53Kd serine kinase converting plas­
minogen into plasmine. It is involved in cancer invasion and metastasis and it has been 
shown to be a prognostic marker in breast cancer. This serine kinase produces degradation 
of extracellular matrix, stimulates mitotic rate and cellular migration, induces cell adhe­
sion molecules expression and promotes angiogenesis. It has been recently demonstrated 
that uPA prevents apoptosis, increasing survival of the malignant cells during metastasis 
and was the first tumor marker that had been clinically evaluated. It is routinely utilized 
to determine the prognosis in patients with breast cancer, especially in advanced stage 
or in indolent course when lymph nodes are negative. Node-negative patients with high 
levels of uPA in breast tumor tissue might benefit with adjuvant therapy, whereas those 
uPA-negative patients can prevent side effects and the cost of the treatment [49].
1.8 Oncogenes and tumour suppressor genes
1.8.1 c-myc gene
c-myc is a gene encoding a nuclear phosphoprotein functioning as a cell cycle regulator. 
In normal cells it rises during phase Gl, but in transformed cells it may be continuously 
expressed during the whole cycle. Amplification of c-myc has been found in breast cancer. 
It is related to a short survival and early recurrence of the disease. Genetic alterations of 
c-myc oncogen play a key role in induction and progression of breast cancer. Its ampli­
fication is related to a poor prognosis not only in lobular but also in ductal carcinoma. 
It does not seem to be associated to other prognostic factors. When c-myc gene is not 
altered, the presence of the protein is related to a low incidence of metastasis in axillary 
lymph nodes [50].
1.8.2 Rb gene
Gene family of retinoblastoma , one of the best studied tumor suppressor genes, consists 
of three members: gene product (pRb) and two related proteins: pRb2/130 and pl07, 
which are structural and functionally similar to pRb. All of them show properties of 
inhibiting growth cell. pRb2/130 is a possible target to be used in gene therapy [51].
1.8.3 E2F-1
E2F1 protein is a nuclear transcription factor whose activity is regulated by Rb protein. 
Its increase is correlated to other prognostic factors such as tumour grade, metastasis, 
ER, PgR and p53. Therefore, it could be used as a prognostic marker [52],
1.8.4 Heat shock proteins (Hsps)
Some of the highly conserved heat shock proteins also called stress response proteins, 
such as Hsp27 is constitutively expressed in normal tissue breast. In malignant cells, 
overexpression of this molecule is frequently found. Most authors find correlation between 
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Hsp 27 overexpression, ER, metastatic lymph nodes and vascular invasion. According to 
these parameters, the protein could be a marker of tumour aggressiveness [53, 54],
It has been observed that Hsp27 induces resistance to chemotherapy. The modulation 
of expression levels of Hsp could be used in clinical application in order to be in detriment 
of the resistance to drugs and control tumoral growth [55].
In experiments performed in our laboratory [56], we demonstrated that there is a 
significant correlation between the absence of Hsp 27 expression by tumour cells of breast 
cancer and the presence of metastasis in axillary nodes. Its highest expression is correlated 
with early stages of breast cancer.
1.8.5 Cytokeratins
Cytokeratin-19: the molecular study with PCR of mRNA positive cells for CK-19 in 
peripheral blood of patients with breast cancer is the most sensitive method and allows 
the detection of occult tumour cells. Several studies have shown that this protein can be 
detected in patients before or after the treatment with chemotherapy drugs [57, 58].
1.9 Adhesion molecules
1.9.1 Ep-CAM
Epithelial cell adhesion molecule (Ep-CAM) is a glycoprotein expressed in most epithelia 
and in tumours derived from this tissue. Ep-cam overexpression is an indicator of a poor 
prognosis, independent of other parameters like tumour size, histological grade, expression 
of hormonal receptors and c-erbB-2 [59, 60].
1.9.2 Alcam
Activated leucocyte cell adhesion molecule (ALCAM) is a molecule intervening in cellular 
migration. It belongs to the superfamily of immunoglobulines and is expressed in the 
normal breast. Its decreased expression in breast cancer would be associated to a more 
aggressive phenotype and poor prognosis [61].
2 Conclusions
The identification of new biological and molecular indicators of clinical outcome and the 
response to therapy in patients with breast cancer has been an area of active investigation 
during the last two decades. Although numerous biological and molecular markers have 
been identified during this period, traditional factors such as lymph node status, tumour 
size, histological type, histological grade and hormone receptor status remain as the 
most useful indicators of prognosis and therapeutic response. Recent advances in the 
understanding of breast cancer biology have made it possible to develop new molecular 
markers, with potential utility in identification, screening, prognosis, detection and moni­
toring. Nevertheless, it is difficult to translate research advances into prognostic and 
predictive markers that are useful in clinical management.
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In 1999, a multidisciplinary group of pathologists, clinicians and statisticians reviewed 
prognostic and predictive factors of breast cancer and categorized them into three groups 
reflecting their clinical utility.
Category I: Well supported by the literature. They are generally used in patient mana­
gement (tumour size, lymph node status, histological type, histological grade, mitotic- 
index, and hormone receptor status). Sentinel node biopsy is added.
Category II: Markers have been extensively studied biologically, clinically or both and 
tested in clinical trials, but more studies are necessary to statistically validate, c-erbB-2, 
p53, vascular invasion and proliferation markers like Ki-67 or PCNA. C-erbB-2 is mainly 
utilized in patients with advanced breast cancer in order to evaluate the potential response 
to Trastuzumab [62],
Category III: Any other factors not sufficiently studied to demonstrate their prognostic­
value (ploidy, cathepsin D, intratumoral angiogenesis, EGFR, Bcl-2).
The determination of tumour angiogenesis expressed as density of microvessels by 
microscopic held is considered of great importance since there are papers supporting this 
correlation with the grade of neoplastic proliferation in breast cancer and also with the 
prediction of micrometastasis in bone marrow in clinically metastasis-free patients [63].
Recommendations are presented for the routine clinical use of serum and tissue-based 
markers in the diagnosis and management of patients with breast cancer. Their low 
sensitivity and specificity preclude the use of serum markers such as the MUC-1 mucin 
glycoproteins (CA 15.3, BR 27.29) and CEA in the diagnosis of early breast cancer, but 
their serial measurement can be useful in early detection of recurrences.
Since breast cancer is a hormone-dependent cancer, estrogen and progesterone recep­
tor status is important to predict the likelihood of response to hormonal therapies.
Her-2 detection may support selection of optimal therapy for breast cancer patients 
with antibody directed against this protein or adjuvant chemotherapy in advanced breast 
cancer. Mucin CA 15.3 is used to monitor the efficacy of treatment and detect recurrences. 
CA 27.29 may predict disease relapses and can be used to detect when the treatment 
fails [64],
Urokinase plasminogen activator (uPA) has been recently validated as prognostic­
markers in patients with breast cancer and metastasis- free lymph nodes and thus may 
be of value in selecting node-negative patients that do not require adjuvant chemotherapy 
[65].
Although high Ki-67 is a sign of poor prognosis, it is associated with a good chance 
of clinical response to chemotherapy. Its independent significance is modest and does 
not merit measurement in clinical routine. However, this molecule is becoming a useful 
tool for evaluation of the effectiveness of medical therapy and rapid evaluation of new 
drugs [66]. Based on data of prec-linical models, several antiangiogenic- compounds have 
been shown to modify activated tumour endothelium, suggesting that these compounds 
can improve cytotoxic drug delivery [67].
This brief and concise review describes both traditional and new molecular bio­
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markers with great potential to become useful tools to determine prognosis, detect recur­
rences, design therapeutic strategies and monitor treatment in breast cancer.
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